AG·尊龙凯时

News & Trends

• 272022-05

  Updated progress of Allisartan Isoproxil and Indapamide sustained-release tablets in Phase 3 trial for the treatment of essential hypertension

• 242022-05

  Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer

• 262022-04

  Teriparatide Injection (Xinfutai Pro®) for Osteoporosis Approved for Commercialization

• 092022-03

  Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases

• 042022-03

  NMPA Approves Clinical Trials with SAL0114 Tablets for AD Agitation

• 172022-02

  Salubris Announces Clinical Trial Approval of SAL0114 Tablet – Potential Clinical Depression Treatment Candidate